TUTORIALSNov 4, 2026 · 1 min read
UBS Maintains Buy on Amgen, Raises Price Target to $530
By Benzinga Newsdesk
UBS analyst Michael Yee maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $470 to $530.
Share this article
Keep reading.
Trade what
you just read.
Apply the analysis on a live or demo account, same execution, no risk on demo.
Your seat at the market is ready.
Open your account in minutes, transparent pricing, fast withdrawals and support that answers.

